ADMA Biologics (ADMA) Puts Growth Narrative To The Test As Fair Value Stays In Focus

Simply Wall St.07-15

Adma Biologics (ADMA) drew fresh attention after its stock fell 1.21%, trailing broader indices, as investors looked ahead to an earnings release in which analysts expect higher earnings per share and...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2651009435?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-07-15 09:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2651009435","market":"us","top_or_hot":-1,"title":"ADMA Biologics (ADMA) Puts Growth Narrative To The Test As Fair Value Stays In Focus","media":"Simply Wall St.","content":"<div>\n<p>Adma Biologics (ADMA) drew fresh attention after its stock fell 1.21%, trailing broader indices, as investors looked ahead to an earnings release in which analysts expect higher earnings per share and...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adma/adma-biologics/news/adma-biologics-adma-puts-growth-narrative-to-the-test-as-fai\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ADMA Biologics (ADMA) Puts Growth Narrative To The Test As Fair Value Stays In Focus</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nADMA Biologics (ADMA) Puts Growth Narrative To The Test As Fair Value Stays In Focus\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-15 09:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adma/adma-biologics/news/adma-biologics-adma-puts-growth-narrative-to-the-test-as-fai><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Adma Biologics (ADMA) drew fresh attention after its stock fell 1.21%, trailing broader indices, as investors looked ahead to an earnings release in which analysts expect higher earnings per share and...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adma/adma-biologics/news/adma-biologics-adma-puts-growth-narrative-to-the-test-as-fai\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ADMA","symbol_name":"ADMA Biologics Inc","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adma/adma-biologics/news/adma-biologics-adma-puts-growth-narrative-to-the-test-as-fai","article_id":"2651009435","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adma/adma-biologics/news/adma-biologics-adma-puts-growth-narrative-to-the-test-as-fai","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2651009435","pubTimestamp":1784078694,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Adma Biologics (ADMA) drew fresh attention after its stock fell 1.21%, trailing broader indices, as investors looked ahead to an earnings release in which analysts expect higher earnings per share and revenue compared with last year.\nSee our latest analysis for ADMA Biologics.\nAt a share price of $8.87, ADMA Biologics has seen short term momentum soften, with the share price return down over the past week and quarter, while a very large 5 year total shareholder return shows how strong earlier...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"ADMA":"ADMA Biologics Inc","BK4139":"生物科技"},"translate_title":"ADMA Biologics (ADMA) 对增长叙事进行考验，公允价值仍然是焦点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADMA":1.5},"content_text":"Adma Biologics (ADMA) drew fresh attention after its stock fell 1.21%, trailing broader indices, as investors looked ahead to an earnings release in which analysts expect higher earnings per share and revenue compared with last year. See our latest analysis for ADMA Biologics. At a share price of $8.87, ADMA Biologics has seen short term momentum soften, with the share price return down over the past week and quarter, while a very large 5 year total shareholder return shows how strong earlier gains have been. Recent price weakness, alongside anticipation around the upcoming earnings release, suggests investors are reassessing both growth potential and risk after a long period of strong total returns. If this kind of reassessment has you looking beyond a single stock, it could be a good moment to scan for other ideas in healthcare related AI, starting with 40 healthcare AI stocks. ADMA Biologics now appears to be a solid plasma-based business whose stock has stumbled, which puts the focus squarely on price. After such sharp long term gains, is the current valuation still reasonable? AdvertisementMost Popular Narrative: 49.6% Undervalued With ADMA Biologics last closing at $8.87 against a narrative fair value of $17.60, the current market price sits well below what this widely followed valuation framework implies.  Expansion of plasma collection volumes and the acquisition of new facilities are set to increase production capacity and supply chain resilience, positioning ADMA to capture greater market share and further accelerate revenue growth and earnings over the long term.  Read the complete narrative. Want to see how this outlook turns into that fair value for ADMA Biologics? The narrative leans heavily on future revenue, margins and the earnings multiple that ties it all together. Result: Fair Value of $17.60 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, the ADMA Biologics story could shift quickly if the plasma yield process runs into setbacks or if ongoing class action lawsuits weigh further on sentiment. Find out about the key risks to this ADMA Biologics narrative. Next Steps If sentiment around ADMA Biologics feels mixed, this is a good time to move quickly and check the underlying facts yourself. To see what investors are optimistic about, take a closer look at the 3 key rewards. Looking for more investment ideas beyond ADMA Biologics? If you are weighing what comes next after ADMA Biologics, do not stop here. Fresh opportunities often appear where fewer investors are already looking.  Spot potential bargains early by checking out screener containing 20 high quality undiscovered gems before they move onto everyone else's radar. Focus on financial strength first by using the solid balance sheet and fundamentals stocks screener (48 results) to concentrate on companies with sturdier fundamentals. Prioritize stability in uncertain markets and use the 79 resilient stocks with low risk scores to narrow in on businesses with lower overall risk profiles.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2651009435","isCrawlerRequest":true}